Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526902 · ClinicalTrials.gov registry record · NA
Proclear 1-D Multifocal Nondispensing Study
A NA study, sponsored by CooperVision.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT01526902: Completed NA study, sponsored by CooperVision.
NCT01526902 is a NA study that has completed, run by CooperVision. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01526902, a NA study, has completed, sponsored by CooperVision.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is designed to compare the relative performance related to subjective and objective vision between two multifocal soft contact lenses.
Primary Outcome
Tested with charts distant to the subject with both eyes together in normal lighting conditions. The unit of measure is logMAR units (logarithm of the minimum angle of resolution) A logMAR acuity of 0.0 equates to 20/20 Snellen acuity. Positive logMAR values indicate poorer vision and negative values denote better visual acuity than baseline 20/20 value.
Interventions
- DEVICE omafilcon A / PC 1-D MF
- DEVICE lotrafilcon B / Air Optix MF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-05 |
| Phase | NA |
What the finished NCT01526902 record still lists
NCT01526902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which omafilcon A / PC 1-D MF is the first listed.
NCT01526902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01526902 about?
NCT01526902 is a clinical study titled "Proclear 1-D Multifocal Nondispensing Study". This study is designed to compare the relative performance related to subjective and objective vision between two multifocal soft contact lenses.
What is the current status of trial NCT01526902?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2012-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01526902?
The interventions under investigation include: omafilcon A / PC 1-D MF (DEVICE), lotrafilcon B / Air Optix MF (DEVICE).
Who is sponsoring clinical trial NCT01526902?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01526902's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia